TY - JOUR
T1 - Corrigendum to “Risk factors for early-onset pancreatic ductal adenocarcinoma
T2 - A systematic literature review” [Eur J Cancer 198 (2024) 113471] (European Journal of Cancer (2024) 198, (S0959804923007736), (10.1016/j.ejca.2023.113471))
AU - Chandana, Sreenivasa R.
AU - Woods, Laura M.
AU - Maxwell, Fiona
AU - Gandolfo, Ruth
AU - Bekaii-Saab, Tanios
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/4
Y1 - 2024/4
N2 - The authors regret that Dr Zhimin Xiao's involvement as an author of this manuscript was unfortunately overlooked. We, the authors, would like to include Dr Zhimin Xiao, who was employed by Ipsen during manuscript development. We propose to include Dr Zhimin Xiao as the fourth author. Dr Zhimin Xiao made significant contributions to the development of this manuscript. The author details for Dr Zhimin Xiao are as follows: previously an employee of Ipsen; no other conflicts of interest. His contributions include: Conceptualisation; Methodology; Visualisation; Writing - review & editing. The authors would like to apologise for any inconvenience caused. The corrected authorship of this article is as follows: Sreenivasa R. Chandanaa,*, schandana@chcwm.com, Laura M. Woodsb, Fiona Maxwellc, Zhimin Xiaod, Ruth Gandolfoe, Tanios Bekaii-Saabf aDepartment of Gastrointestinal Medical Oncology, The Cancer and Hematology Centers, Grand Rapids, MI, USA bPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK cIpsen, Slough, UK dIpsen, Cambridge, MA, USA eOxford PharmaGenesis, Oxford, UK fDepartment of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA *Corresponding author.
AB - The authors regret that Dr Zhimin Xiao's involvement as an author of this manuscript was unfortunately overlooked. We, the authors, would like to include Dr Zhimin Xiao, who was employed by Ipsen during manuscript development. We propose to include Dr Zhimin Xiao as the fourth author. Dr Zhimin Xiao made significant contributions to the development of this manuscript. The author details for Dr Zhimin Xiao are as follows: previously an employee of Ipsen; no other conflicts of interest. His contributions include: Conceptualisation; Methodology; Visualisation; Writing - review & editing. The authors would like to apologise for any inconvenience caused. The corrected authorship of this article is as follows: Sreenivasa R. Chandanaa,*, schandana@chcwm.com, Laura M. Woodsb, Fiona Maxwellc, Zhimin Xiaod, Ruth Gandolfoe, Tanios Bekaii-Saabf aDepartment of Gastrointestinal Medical Oncology, The Cancer and Hematology Centers, Grand Rapids, MI, USA bPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK cIpsen, Slough, UK dIpsen, Cambridge, MA, USA eOxford PharmaGenesis, Oxford, UK fDepartment of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA *Corresponding author.
UR - http://www.scopus.com/inward/record.url?scp=85186544671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186544671&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2024.113941
DO - 10.1016/j.ejca.2024.113941
M3 - Comment/debate
C2 - 38433045
AN - SCOPUS:85186544671
SN - 0959-8049
VL - 201
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 113941
ER -